GlassScriptPhysician profile
Patricia Jackson
NPI 1326146036
$5,174.37
in general payments reported to CMS, 2019-2025
35 companies · $837 in 2025
The $837 reported for 2025 was more than what 82% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $667 · 2020: $678 · 2021: $669 · 2022: $619 · 2023: $830 · 2024: $875 · 2025: $837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,542.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,541.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $765.55 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $761.01 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $632.63 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $462.82 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $415.77 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $411.22 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $260.50 | 2019-2025 | Freestyle Libre |
| Pfizer INC. | $201.58 | 2022-2025 | |
| Astellas Pharma US INC | $151.77 | 2019-2025 | Veozah |
| Esperion Therapeutics, INC. | $92.26 | 2020-2023 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $91.23 | 2021-2025 | |
| Glaxosmithkline, LLC. | $81.03 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $77.31 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $72.77 | 2019-2024 | Capvaxive, Gardasil 9, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.03 | 2019-2024 | Trulance, Xifaxan, Relistor |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $70.56 | 2023-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $50.99 | 2019-2022 | |
| Eisai INC. | $49.77 | 2020-2021 | |
| Allergan, INC. | $49.25 | 2019-2020 | |
| Idorsia Pharmaceuticals US INC | $48.02 | 2022-2023 | Quviviq |
| Biohaven Pharmaceuticals, INC. | $43.75 | 2021 | |
| Exact Sciences Corporation | $39.26 | 2023-2025 | Cologuard Collection Kit |
| Gilead Sciences, INC. | $36.78 | 2020-2025 | |
| Inspire Medical Systems, INC. | $31.81 | 2025 | Inspire |
| Takeda Pharmaceuticals U.S.A., INC. | $29.23 | 2023 | Trintellix |
| Jazz Pharmaceuticals INC. | $26.05 | 2022 | |
| Novartis Pharmaceuticals Corporation | $24.16 | 2021-2022 | |
| Seqirus USA INC | $20.64 | 2025 | Fluad, Flucelvax |
| Sunovion Pharmaceuticals INC. | $20.19 | 2022 | |
| Amarin Pharma, INC. | $18.21 | 2020 | |
| Mylan Specialty L.P. | $15.39 | 2022 | |
| Sanofi Pasteur INC. | $13.72 | 2020 | |
| Circassia INC. | $13.54 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.52 | 2023 | Livalo, Seglentis |
| Teva Pharmaceuticals USA, INC. | $11.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.